MASLD New Era In modern clinical practice, one of the most commonly seen conditions is a fatty liver. Traditionally, we used to divide it into alcoholic and non-alcoholic fatty liver disease (NAFLD). The issue with this approach was that the diagnosis of NAFLD didn’t provide much guidance about future management. Which is why the medical community has now shifted to a more precise diagnosis: MASLD or Metabolic Dysfunction-Associated Steatotic Liver Disease.
And this change is because we now understand that a fatty liver isn’t an isolated problem, but the hepatic manifestation of metabolic syndrome. In fact, MASLD is specifically tied to at least one cardiometabolic risk factor, such as Type 2 Diabetes, obesity, or hypertension.
MASLD vs NAFLD: MASLD New Era
The old term, NAFLD, was a diagnosis of exclusion. It defined the condition by what you weren’t doing, more specifically, it meant you had a fatty liver and you weren’t drinking excessive alcohol. It told us nothing about the actual cause of the fat, and lacked diagnostic precision.
MASLD, on the other hand, is a diagnosis of inclusion. It requires a more detailed investigative strategy, and to meet the criteria, a patient must have:
- Hepatic steatosis, evidenced by visible fat on an ultrasound or FibroScan.
- At least one metabolic risk factor, either high BMI, Type 2 Diabetes, hypertension, or elevated triglycerides.
Difference Between MASH and MASLD:
MASLD and MASH can be understood as points on the spectrum of severity, with the final point being extensive scarring and cirrhosis.
Simple Steatosis (MASLD)
This is the entry point. At this stage, > 5% of your liver’s weight is made up of fat. While this stage is often silent, it is the primary cause of hepatomegaly (an enlarged liver) seen on routine ultrasounds. At this stage, there is no significant inflammation or scarring to the liver yet.
The Active Phase (MASH)
When the fat starts triggering inflammation, we call it Metabolic Dysfunction-Associated Steatohepatitis. In this stage, there is ‘ballooning’ and death of liver cells. This is the critical point of no return, where the risk of permanent scarring begins.
3. Cirrhosis
When the liver goes through years of chronic inflammation (MASH), it replaces its functional tissue with hard, fibrous scar tissue. This is terminal scarring, or cirrhosis, which can lead to liver failure or even Hepatocellular Carcinoma (liver cancer).
The Evolutionary Spectrum of MASLD. The clinical continuum from simple steatosis to MASH , where immunological mechanisms trigger the second hit of liver damage. This inflammatory phase is the primary driver toward irreversible fibrosis, terminal cirrhosis, and eventually, liver cancer. Identifying the disease at the steatosis stage allows for a window of metabolic repair before permanent scarring begins. (Image Courtesy: He, Y., Chen, Y., Qian, S. et al. Immunopathogenic mechanisms and immunoregulatory therapies in MASLD. Cell Mol Immunol 22 , 1159–1177 (2025). Available from nature and licensed under CC by 4.0)
What is Lean MASLD
A common clinical misconception is that MASLD only affects someone who is visibly obese with a high BMI. That is not true; we frequently see MASLD with a significant fatty liver in patients with a normal body weight.
The reason is simple: visceral fat, the fat around vital organs, is far less visible than subcutaneous fat. Asians often are genetically predisposed to store fat as a result of distant adaptation over centuries, as famines in Asia had the capacity to wipe out entire populations.
A well-known gene responsible for this is PNPLA3, and it instructs the liver to store fat in the Asian body, even in a young patient, and even if they have a normal BMI. This is why you can never depend on a good BMI to indicate liver health.
Clinical Symptoms and Signs
The reason that a MASLD liver is so dangerous is that it remains silent. Hepatic steatosis in and of itself doesn’t cause pain. Instead, it is often discovered as a secondary finding during a workup for some other condition or as part of a routine examination.
Early Warning Signs
Most patients with simple MASLD are asymptomatic, but as the liver begins to swell, you may notice:
- Patients complain of a brain fog or exhaustion that doesn’t improve with sleep. We call this metabolic fatigue.
- Right upper quadrant heaviness: The patient typically is unable to describe it as pain, but rather pressure, discomfort, or dull ache below the ribs. This is usually from the physical stretching of the liver capsule (Glisson’s Capsule) as the liver enlarges. This is also how we usually find hepatomegaly, being incidental, on an ultrasound or physical exam.
- Acanthosis Nigricans, which are dark, velvety patches of skin around the neck or armpits. These are visible signs of insulin resistance, which usually leads to MASLD.
As MASH continues unchecked, the cycle of inflammation and repair creates scar tissue. This eventually becomes MASLD Cirrhosis, the stage of no return. Signs and symptoms of cirrhosis are unmistakable and may include:
- Yellowing of the skin or eyes (jaundice)
- Fluid retention resulting in swelling in the legs (edema) or abdomen (ascites)
- Patients bruise very easily, which is a tell-tale sign that the liver is no longer producing enough clotting factors.
The Diagnostic Gold Standard in 2026
Because we no longer depend on a diagnosis of exclusion, we don’t stop at liver enzyme profiles and ultrasounds to diagnose NAFLD. For MASLD, we need to quantify the damage.
- Abdominal ultrasound is still usually where the first finding of steatosis is made; the liver is seen as bright or echogenic. For reference, we compare the brightness of the liver to that of the kidney.
- FibroScan (Transient Elastography) is very helpful in what we call a non-invasive ‘virtual biopsy’ that measures two things: the amount of fat (CAP score) and the stiffness of the liver (Fibrosis score). The stiffer the liver, the more scarring (fibrosis) is present.
- In regards to blood tests, we look for elevated ALT and AST levels, but we also calculate the FIB-4 score, a simple formula that helps predict if you are moving toward advanced scarring.
The FIB-4 Index. A non-invasive ‘virtual biopsy’ calculation used to screen for advanced liver scarring (fibrosis) in patients with MASLD/NAFLD. It integrates readily available blood test results—AST, ALT, and Platelet Count—with age to generate a score. (Note: Clinical guidelines often use a 2.0 low cut-off for patients > 65 years).
Management of MASLD
Can MASLD be reversed? Yes, in fact, it is one of the few chronic conditions that are highly reversible in their early stages. Because it is a metabolic disease, the cure is also metabolic repair. It is mainly treated by addressing the underlying metabolic risk factors rather than a single specific medication.
1. The 7% Weight Loss Rule
Clinical research and data paint a very clear picture: losing just 7 to 10% of your total body weight can physically clear the fat out of your liver cells and, in many cases, even reverse early-stage fibrosis because of inflammation.
2. Resistance Training
Exercise in general is recommended, but while cardio is great for the heart, resistance training is particularly effective for MASLD. Muscle tissue actually acts as a sink for glucose, pulling excess sugar out of the bloodstream and preventing the liver from converting that excess energy into fat.
3. Lifestyle Changes
We move away from the traditionally preached low-fat diet and focus on low-glycemic dietary habits. By reducing refined sugars, we lower insulin levels. When insulin is low, the liver is finally allowed to enter fat-burning mode.
A lot of people don’t realize this, but emerging science tells us that your gut health directly affects your liver. A leaky gut or SIBO (Small Intestinal Bacterial Overgrowth) can allow toxins to travel by the portal vein directly to the liver, and that sets off inflammation. A diet rich in fiber and fermented foods helps seal the gut-liver barrier.
The Gut–Liver Axis and NAFLD Progression. When the intestinal barrier , composed of mucus, cells, immune defenses, and blood vessels (GVB), is compromised, it creates a ‘leaky gut.’ This allows bacteria and inflammatory toxins from the gut to travel directly to the liver via the portal vein, acting as a major hidden driver for hepatic steatosis symptoms and MASLD/NAFLD progression . Simultaneously, the liver regulates gut health through the circulation of bile acids, creating a complex, bidirectional highway that is central to managing metabolic liver health. (Image Courtesy: Song, Q., & Zhang, X. (2022). The Role of Gut–Liver Axis in Gut Microbiome Dysbiosis Associated with NAFLD and NAFLD-HCC. Biomedicines, 10(3), 524. Available from MDPI and licensed under CC by 4.0)
Medical Management of Metabolic Risk Factors
Because Metabolic Dysfunction-Associated Steatotic Liver Disease is closely linked to metabolic syndrome, treatment also focuses on controlling conditions such as Type 2 Diabetes, hypertension, and dyslipidemia. Proper management of blood sugar, blood pressure, and cholesterol helps slow disease progression and reduces cardiovascular risk.
Monitoring and Long-Term Follow-Up
Patients with MASLD often require periodic monitoring using blood tests, fibrosis scores, and imaging. Those with advanced fibrosis may need surveillance for complications such as Hepatocellular Carcinoma.
Final Word
MASLD is the most common liver disease in the world. We consider it to be part of the normal disease spectrum for the same reason that we all, both patients and providers, view type II diabetes and heart disease as ‘normal.’ We propagate its acceptance as a normal state of aging and allow it to grow in our population because of our sugar-heavy diets and sedentary lifestyles.
While this is true and those factors certainly predispose the liver to MASLD, it is not simply an unavoidable, progressive end. More importantly, most of the time, the initial insult to the liver only really causes steatosis, but if left unmanaged, it becomes MASH, and further, it will cause hepatic cirrhosis. So a huge window of time is usually available for intervention in most patients. But most of the time, we don’t do anything until after irreversible damage (cirrhosis) has occurred. Since we know hepatomegaly can be tied to more severe metabolic issues like diabetes, it is imperative that we educate ourselves on a healthy lifestyle.
References
[1] Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature.J Hepatol.2023;79(6):1542–1556. doi:10.1016/j.jhep.2023.06.003.
[2] Chan, W. K., Chuah, K. H., Rajaram, R. B., Lim, L. L., Ratnasingam, J., & Vethakkan, S. R. (2023). Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review. Journal of obesity & metabolic syndrome, 32(3), 197–213.
[3] Papatheodoridi, M., & Cholongitas, E. (2018). Diagnosis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Concepts. Current pharmaceutical design, 24(38), 4574–4586.
[4] Luthra, R., & Sheth, A. (2025). Understanding MASH: An Examination of Progression and Clinical Outcomes by Disease Severity in the TARGET-NASH Database. Advances in therapy, 42(2), 1165–1195.
[5] Williams, R., & Periasamy, M. (2020). Genetic and Environmental Factors Contributing to Visceral Adiposity in Asian Populations. Endocrinology and metabolism (Seoul, Korea), 35(4), 681–695.
[6] Blanco-Grau, A., Gabriel-Medina, P., Rodriguez-Algarra, F., Villena, Y., Lopez-Martínez, R., Augustín, S., Pons, M., Cruz, L. M., Rando-Segura, A., Enfedaque, B., Riveiro, M., Casis, E., Ferrer-Costa, R., Buti, M., & Rodriguez-Frias, F. (2021). Assessing Liver Fibrosis Using the FIB4 Index in the Community Setting. Diagnostics (Basel, Switzerland), 11(12), 2236.
[7] Niu, J., Al-Yaman, W., Pinyopornpanish, K., Park, J. S., Salazar, M., Xiao, H., Bena, J., Lyu, R., Flocco, G., Junna, S. R., Adhami, T., Sims, O. T., & Wakim-Fleming, J. (2024). The Long-Term Effect of Weight Loss on the Prevention of Progression to Cirrhosis among Patients with Obesity and MASH-Related F3 Liver Fibrosis. International journal of environmental research and public health, 21(6), 708.
[8] Augustyn, M., Grys, I., & Kukla, M. (2019). Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease. Clinical and experimental hepatology, 5(1), 1–10.